JP2022554395A - がんを処置するためのスプライシング由来抗原の同定 - Google Patents

がんを処置するためのスプライシング由来抗原の同定 Download PDF

Info

Publication number
JP2022554395A
JP2022554395A JP2022526337A JP2022526337A JP2022554395A JP 2022554395 A JP2022554395 A JP 2022554395A JP 2022526337 A JP2022526337 A JP 2022526337A JP 2022526337 A JP2022526337 A JP 2022526337A JP 2022554395 A JP2022554395 A JP 2022554395A
Authority
JP
Japan
Prior art keywords
cells
tcr
peptide
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554395A5 (https=
JPWO2021092436A5 (https=
Inventor
イー シン
ロバート プリンス
ヤン パン
アレクサンダー エイチ． リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022554395A publication Critical patent/JP2022554395A/ja
Publication of JP2022554395A5 publication Critical patent/JP2022554395A5/ja
Publication of JPWO2021092436A5 publication Critical patent/JPWO2021092436A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022526337A 2019-11-08 2020-11-06 がんを処置するためのスプライシング由来抗原の同定 Pending JP2022554395A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962932751P 2019-11-08 2019-11-08
US62/932,751 2019-11-08
US201962934914P 2019-11-13 2019-11-13
US62/934,914 2019-11-13
PCT/US2020/059476 WO2021092436A1 (en) 2019-11-08 2020-11-06 Identification of splicing-derived antigens for treating cancer

Publications (3)

Publication Number Publication Date
JP2022554395A true JP2022554395A (ja) 2022-12-28
JP2022554395A5 JP2022554395A5 (https=) 2023-11-14
JPWO2021092436A5 JPWO2021092436A5 (https=) 2023-11-14

Family

ID=75849568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526337A Pending JP2022554395A (ja) 2019-11-08 2020-11-06 がんを処置するためのスプライシング由来抗原の同定

Country Status (5)

Country Link
US (1) US20220380937A1 (https=)
EP (1) EP4055182A4 (https=)
JP (1) JP2022554395A (https=)
CN (1) CN115968406A (https=)
WO (1) WO2021092436A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144021A1 (en) * 2019-01-09 2020-07-16 British Telecommunications Public Limited Company Anomalous behaviour detection in a distributed transactional database
JP2023513605A (ja) * 2020-02-14 2023-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを処置するためのスプライシング由来抗原を含む組成物および方法
EP4423116A4 (en) * 2021-10-25 2025-12-17 Univ California METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLIOBLASTOM
EP4201954A1 (en) * 2021-12-22 2023-06-28 Christian-Albrechts-Universität zu Kiel Proteins and t-cells involved in chronic inflammatory diseases
US20250277013A1 (en) * 2022-05-04 2025-09-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts T cell receptor derived binding polypeptides
CN114891885A (zh) * 2022-05-04 2022-08-12 重庆大学附属肿瘤医院 Hdhd5-as1长链非编码rna水平检测试剂在制备卵巢癌干性诊断试剂中的应用
WO2024044786A2 (en) * 2022-08-26 2024-02-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel cd4+ tumor infiltrating lymphocytes for the treatment of cancer
US20260027153A1 (en) * 2023-01-17 2026-01-29 The Regents Of The University Of California Therapeutic polynucleotides encoding t cell receptor (tcr) alpha chain polypeptides and/or tcr beta chain polypeptides
WO2025050009A2 (en) * 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
US20190279742A1 (en) * 2017-10-10 2019-09-12 Gritstone Oncology, Inc. Neoantigen identification using hotspots
WO2021163562A2 (en) * 2020-02-14 2021-08-19 The Regents Of The University Of California Compositions and methods comprising splicing-derived antigens for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10130693B2 (en) * 2015-08-28 2018-11-20 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
US20190279742A1 (en) * 2017-10-10 2019-09-12 Gritstone Oncology, Inc. Neoantigen identification using hotspots
WO2021163562A2 (en) * 2020-02-14 2021-08-19 The Regents Of The University Of California Compositions and methods comprising splicing-derived antigens for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG, P ET AL.: "IRIS: Big data-informed discovery of cancer immunotherapy targets arising from pre-mRNA alternative", BIORXIV, JPN6024047552, 15 November 2019 (2019-11-15), ISSN: 0005467402 *

Also Published As

Publication number Publication date
WO2021092436A1 (en) 2021-05-14
EP4055182A4 (en) 2024-07-03
EP4055182A1 (en) 2022-09-14
CN115968406A (zh) 2023-04-14
US20220380937A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US11939389B2 (en) BCMA chimeric antigen receptors and uses thereof
JP2022554395A (ja) がんを処置するためのスプライシング由来抗原の同定
US12214037B2 (en) Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
ES2900233T3 (es) Moléculas que se unen a CD70 y métodos de uso de las mismas
AU2014366047B2 (en) Human mesothelin chimeric antigen receptors and uses thereof
US20240269179A1 (en) Neoantigens as targets for immunotherapy
JP2021526814A5 (https=)
KR20220034782A (ko) 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
US20250230244A1 (en) Methods and compositions comprising b7-h3 binding polypetides
JP2023513605A (ja) がんを処置するためのスプライシング由来抗原を含む組成物および方法
JP2021512637A (ja) サイクリンａ１特異的ｔ細胞受容体およびその使用
HK40092056A (zh) 用於治疗癌症的剪接衍生抗原的鉴定
WO2025050009A2 (en) Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20250049848A1 (en) Methods and compositions for altering a tumor microbiome
WO2025035133A1 (en) Bmp-7 antibody compositions & methods for treating cancer

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250731